Erasca: A Credible Rival to Revolution's Daroxonrasib at a Cheaper Price Point

This Seeking Alpha article by biotech consultant Edmund Ingham analyzes Erasca, Inc. (ERAS), a San Diego-based biotech developing therapies for RAS/MAPK pathway-driven cancers. The author positions Erasca as a credible competitor to Revolution Medicines' daroxonrasib, but at a more attractive valuation. The piece includes the analyst's disclosure of a potential long position in ERAS within 72 hours, and promotes the author's investing group Haggerston BioHealth. The article provides context on the biotech sector and the author's background, but does not present breaking news; it is an investment opinion piece focused on stock valuation and competitive positioning.

First published Aug 4, 01:59 PM UTCUpdated Jul 17, 09:14 PM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 17, 09:14 PM UTCEditorial record as of Aug 4, 01:59 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

currentJul 17, 09:14 PM UTC

Erasca: A Credible Rival to Revolution's Daroxonrasib at a Cheaper Price Point

Coverage sources

External reporting used to assemble this Story.

Erasca: A Credible Rival to Revolution's Daroxonrasib at a Cheaper Price PointAll Articles on Seeking AlphaWesternJul 17, 09:14 PM UTC

Follow the context

San Diego